Exercise Pulmonary Hypertension in Patients with Systemic Sclerosis Based on Updated Guidelines

Overview

Journal Sci Rep

Specialty Science

Date 2024 Jun 10

PMID 38858443

Authors

Yu Kanazawa

Ayumi Goda

Takato Mohri

Shinsuke Takeuchi

Kaori Takeuchi

Hanako Kikuchi

Takumi Inami

Kyoko Soejima

Takashi Kohno

Affiliations

Soon will be listed here.

Abstract

Recent European guidelines have introduced the concept of exercise pulmonary hypertension (ex-PH). However, the clinical characteristics of ex-PH in systemic sclerosis (SSc) remains unknown. We aimed to investigate the characteristics of exercise pulmonary hypertension (ex-PH) in patients with systemic sclerosis (SSc), which are unknown. We retrospectively examined 77 patients with SSc who underwent symptom-limited exercise testing using a cycle ergometer with right heart catheterization at our hospital. Nineteen patients with postcapillary PH were excluded. Fifty-eight patients (median age, 63 years; 55 women) were divided into the overt-PH (n = 18, mean pulmonary arterial pressure [PAP] > 20 mmHg and pulmonary vascular resistance > 2 Wood units at rest), ex-PH (n = 19, mean PAP/cardiac output slope > 3), and non-PH (n = 21) groups. Exercise tolerance and echocardiography results were compared among the groups. Peak oxygen consumption was high in the non-PH group, intermediate in the ex-PH group, and low in the overt-PH group (14.5 vs. 13.0 vs. 12.5 mL/kg/min, p = 0.043), and the minute ventilation/peak carbon dioxide production slope was also intermediate in the ex-PH group (32.2 vs. 32.4 vs. 43.0, p = 0.003). The tricuspid annular plane systolic excursion/systolic PAP ratio decreased from non-PH to ex-PH to overt-PH (0.73 vs. 0.69 vs. 0.55 mm/mmHg, p = 0.018). In patients with SSc, exercise PH may represent an intermediate condition between not having PH and overt PH, according to the new guidelines.

References

Kovacs G, Herve P, Barbera J, Chaouat A, Chemla D, Condliffe R . An official European Respiratory Society statement: pulmonary haemodynamics during exercise. Eur Respir J. 2017; 50(5). DOI: 10.1183/13993003.00578-2017. View

Condliffe R, Kiely D, Peacock A, Corris P, Gibbs J, Vrapi F . Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med. 2008; 179(2):151-7. DOI: 10.1164/rccm.200806-953OC. View

Humbert M, Yaici A, de Groote P, Montani D, Sitbon O, Launay D . Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum. 2011; 63(11):3522-30. DOI: 10.1002/art.30541. View

Chua T, Ponikowski P, Harrington D, Anker S, Clark A, Poole-Wilson P . Clinical correlates and prognostic significance of the ventilatory response to exercise in chronic heart failure. J Am Coll Cardiol. 1997; 29(7):1585-90. DOI: 10.1016/s0735-1097(97)00078-8. View

Visovatti S, Distler O, Coghlan J, Denton C, Grunig E, Bonderman D . Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study. Arthritis Res Ther. 2014; 16(6):493. PMC: 4299685. DOI: 10.1186/s13075-014-0493-1. View

Lau E, Godinas L, Sitbon O, Montani D, Savale L, Jais X . Resting pulmonary artery pressure of 21-24 mmHg predicts abnormal exercise haemodynamics. Eur Respir J. 2016; 47(5):1436-44. DOI: 10.1183/13993003.01684-2015. View

Coghlan J, Wolf M, Distler O, Denton C, Doelberg M, Harutyunova S . Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis. Eur Respir J. 2018; 51(4). DOI: 10.1183/13993003.01197-2017. View

Kolstad K, Li S, Steen V, Chung L . Long-Term Outcomes in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS). Chest. 2018; 154(4):862-871. PMC: 6207791. DOI: 10.1016/j.chest.2018.05.002. View

Fauvel C, Raitiere O, Boucly A, de Groote P, Renard S, Bertona J . Interest of TAPSE/sPAP ratio for noninvasive pulmonary arterial hypertension risk assessment. J Heart Lung Transplant. 2022; 41(12):1761-1772. DOI: 10.1016/j.healun.2022.09.005. View

10.

Martis N, Queyrel-Moranne V, Launay D, Neviere R, Fuzibet J, Marquette C . Limited Exercise Capacity in Patients with Systemic Sclerosis: Identifying Contributing Factors with Cardiopulmonary Exercise Testing. J Rheumatol. 2017; 45(1):95-102. DOI: 10.3899/jrheum.161349. View

11.

Douschan P, Kovacs G, Avian A, Foris V, Gruber F, Olschewski A . Mild Elevation of Pulmonary Arterial Pressure as a Predictor of Mortality. Am J Respir Crit Care Med. 2017; 197(4):509-516. DOI: 10.1164/rccm.201706-1215OC. View

12.

Tello K, Axmann J, Ghofrani H, Naeije R, Narcin N, Rieth A . Relevance of the TAPSE/PASP ratio in pulmonary arterial hypertension. Int J Cardiol. 2018; 266:229-235. DOI: 10.1016/j.ijcard.2018.01.053. View

13.

Hassan H, Naranjo M, Ayoub N, Housten T, Hsu S, Balasubramanian A . Improved Survival for Patients with Systemic Sclerosis-associated Pulmonary Arterial Hypertension: The Johns Hopkins Registry. Am J Respir Crit Care Med. 2022; 207(3):312-322. PMC: 9896646. DOI: 10.1164/rccm.202204-0731OC. View

14.

Chung L, Liu J, Parsons L, Hassoun P, McGoon M, Badesch D . Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest. 2010; 138(6):1383-94. PMC: 3621419. DOI: 10.1378/chest.10-0260. View

15.

Brown J, Kotecha T, Steeden J, Fontana M, Denton C, Coghlan J . Reduced exercise capacity in patients with systemic sclerosis is associated with lower peak tissue oxygen extraction: a cardiovascular magnetic resonance-augmented cardiopulmonary exercise study. J Cardiovasc Magn Reson. 2021; 23(1):118. PMC: 8554852. DOI: 10.1186/s12968-021-00817-1. View

16.

Zeder K, Avian A, Bachmaier G, Douschan P, Foris V, Sassmann T . Exercise Pulmonary Resistances Predict Long-Term Survival in Systemic Sclerosis. Chest. 2020; 159(2):781-790. DOI: 10.1016/j.chest.2020.08.2110. View

17.

Huston J, Maron B, French J, Huang S, Thayer T, Farber-Eger E . Association of Mild Echocardiographic Pulmonary Hypertension With Mortality and Right Ventricular Function. JAMA Cardiol. 2019; 4(11):1112-1121. PMC: 6751783. DOI: 10.1001/jamacardio.2019.3345. View

18.

Kovacs G, Olschewski H . Borderline pulmonary pressures in scleroderma - a 'pre-pulmonary arterial hypertension' condition?. Arthritis Res Ther. 2015; 17:123. PMC: 4436164. DOI: 10.1186/s13075-015-0649-7. View

19.

Galie N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):.... Eur Heart J. 2015; 37(1):67-119. DOI: 10.1093/eurheartj/ehv317. View

20.

Condliffe R . Unmasking hidden disease: exercise pulmonary haemodynamics in systemic sclerosis. Eur Respir J. 2017; 50(1). DOI: 10.1183/13993003.00885-2017. View